The Wall Street Journal

Huntington Bankshares, TCF Finanancial agree to merger

Published: Dec. 13, 2020 at 10:39 p.m. ET

By

By Cara Lombardo and Orla McCaffrey

Comments

Combined bank would have around $170 billion in assets

Email icon
Facebook icon
Twitter icon
Linkedin icon
Flipboard icon

Print icon
Resize icon

TCF

HBAN

FITB

KEY

Huntington Bancshares Inc. agreed to merge with TCF Financial Corp. in the latest in a recent string of regional-bank tie-ups.

The all-stock deal would be one of the larger recent bank combinations, valuing Detroit-based TCF TCF, -2.50% at nearly $6 billion, or about an 11% premium. Columbus, Ohio-based Huntington HBAN, -0.77% has a market value of $13 billion.

Together, the banks would have about $170 billion in assets, with a network of branches that stretches from Pennsylvania to Arizona and is especially concentrated in Midwestern states such as Illinois and Michigan.

The deal, if completed, would vault Huntington closer to its fiercest in-state competitors, Fifth Third Bancorp FITB, -1.58% and Key Corp. KEY, -1.49% , which have about $200 billion and $170 billion in assets, respectively.

An expanded version of this report appears on WSJ.com.

Also popular on WSJ.com:

Elon Musk advises CEOs to stop wasting time on PowerPoint, meetings.

How many people have had COVID-19 across the U.S.?

U.S. buys another 100 million COVID-19 vaccine candidate doses: Moderna

Biotech company Moderna Inc. undefined said late Friday the U.S. government has exercised its option to purchase an additional 100 million doses of Moderna's COVID-19 vaccine candidate, which brings the confirmed order commitment to 200 million doses. Moderna said that of the first 100 million doses that the government has bought, 20 million will be delivered by the end of December, with the balance delivered in the first quarter of 2021. Friday's new order will be delivered in the second quarter of 2021, Moderna said. These deliveries are subject, in each case, to an emergency use authorization from the U.S. Food and Drug Administration. The U.S. government has the option to purchase up to an additional 300 million doses of the vaccine candidate from Moderna, and the company expects the vaccination will occur at no cost, as previously announced. The FDA is expected to decide on an EUA for another COVID-19 vaccine candidate, by Pfizer Inc. undefined and BioNTech SE undefined, within days if not sooner. Shares of Moderna rose nearly 4% in the extended session after the news.